These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16769957)

  • 1. No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
    Lorenz D; Hagen K; Ufer M; Cascorbi I; Deuschl G; Volkmann J
    Neurology; 2006 Jun; 66(11):1753-5. PubMed ID: 16769957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
    Kalla R; Spiegel R; Claassen J; Bardins S; Hahn A; Schneider E; Rettinger N; Glasauer S; Brandt T; Strupp M
    J Neuroophthalmol; 2011 Dec; 31(4):320-5. PubMed ID: 21734596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.
    Pahwa R; Lyons KE
    Mov Disord; 2003 May; 18(5):584-7. PubMed ID: 12722174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.
    Zesiewicz TA; Ward CL; Hauser RA; Sanchez-Ramos J; Staffetti JF; Sullivan KL
    Mov Disord; 2007 Jan; 22(2):279-82. PubMed ID: 17149715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor.
    Handforth A; Martin FC
    Mov Disord; 2004 Oct; 19(10):1215-21. PubMed ID: 15390011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
    Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
    Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
    Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of amantadine in essential tremor: a randomized, placebo-controlled trial.
    Gironell A; Kulisevsky J; Pascual-Sedano B; Flamarich D
    Mov Disord; 2006 Apr; 21(4):441-5. PubMed ID: 16229019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carisbamate in essential tremor: brief report of a proof of concept study.
    Elble RJ; Biondi DM; Ascher S; Wiegand F; Hulihan J
    Mov Disord; 2010 Apr; 25(5):634-8. PubMed ID: 20201005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levetiracetam is not effective for essential tremor.
    Elble RJ; Lyons KE; Pahwa R
    Clin Neuropharmacol; 2007; 30(6):350-6. PubMed ID: 18090460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of levetiracetam on essential tremor.
    Bushara KO; Malik T; Exconde RE
    Neurology; 2005 Mar; 64(6):1078-80. PubMed ID: 15781835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zonisamide for essential tremor: an evaluator-blinded study.
    Handforth A; Martin FC; Kang GA; Vanek Z
    Mov Disord; 2009 Feb; 24(3):437-40. PubMed ID: 19117357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.
    Bertorini TE; Rashed H; Zeno M; Tolley EA; Igarashi M; Li YD
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):129-37. PubMed ID: 21321491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
    Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
    Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
    Strupp M; Schüler O; Krafczyk S; Jahn K; Schautzer F; Büttner U; Brandt T
    Neurology; 2003 Jul; 61(2):165-70. PubMed ID: 12874393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
    Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ethanol on the central oscillator in essential tremor.
    Zeuner KE; Molloy FM; Shoge RO; Goldstein SR; Wesley R; Hallett M
    Mov Disord; 2003 Nov; 18(11):1280-5. PubMed ID: 14639668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
    Sprenger A; Zils E; Rambold H; Sander T; Helmchen C
    Ann N Y Acad Sci; 2005 Apr; 1039():395-403. PubMed ID: 15826992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid).
    Melmed C; Moros D; Rutman H
    Mov Disord; 2007 Apr; 22(5):723-7. PubMed ID: 17265458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.
    Tsunemi T; Ishikawa K; Tsukui K; Sumi T; Kitamura K; Mizusawa H
    J Neurol Sci; 2010 May; 292(1-2):81-4. PubMed ID: 20181362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.